An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer

Trial Profile

An Open-Label, Randomized, Multicenter, Phase II, Non Comparative, Exploratory Study on Neoadjuvant Treatment With Trastuzumab Plus Docetaxel Plus Bevacizumab According to Positon Emission Tomography (PET) Value Modification in Patients With Early Stage HER2 Positive Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms AVATAXHER
  • Sponsors Roche
  • Most Recent Events

    • 15 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 22 Feb 2018 Planned End Date changed from 31 Jan 2018 to 28 Feb 2018.
    • 22 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 28 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top